micro-community-banner
Profile Image
  • Saved
The effect of melatonin supplementation on lipid profile, oxidative stress, inflammatory marker, and sleep quality in patients with chronic kidney disease: a GRADE assessed meta-analysis - PubMed

The effect of melatonin supplementation on lipid profile, oxidative stress, inflammatory marker, and sleep quality in patients with chronic kidney disease: a GRADE assessed meta-analysis - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/41727206/

Supplementing with MLT in CKD can gently raise HDL-C levels, decrease oxidative stress, and improve sleep quality. While these effects are encouraging, more extensive and carefully planned clinical trials are...

Meta-analysis of RCTs shows melatonin in CKD modestly increases HDL, reduces oxidative stress, and improves sleep, with no significant effects on other lipids or inflammation; larger trials needed for confirmation.

Profile Image
  • Saved
Improved HDL, LDL and total cholesterol levels following a 3-month administration of Mentha spicata leaf extract and Amaranthus caudatus seed flour extracts, flavonoids and B vitamins. A placebo-controlled, double-blind, randomized clinical trial - PubMed

Improved HDL, LDL and total cholesterol levels following a 3-month administration of Mentha spicata leaf extract and Amaranthus caudatus seed flour extracts, flavonoids and B vitamins. A placebo-controlled, double-blind, randomized clinical trial - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/41519619/

The combination of different FS ingredients with different mechanisms of action can be a valuable strategy for improving lipid profiles in subjects with borderline high TC and LDL-C levels.

Randomized trial shows combined Mentha spicata, Amaranthus, flavonoids, and B vitamins improve lipid profile, reducing LDL and total cholesterol while increasing HDL, especially at higher doses, in borderline dyslipidemia patients.

Profile Image
  • Saved
Incretin polyagonists as an alternative to bariatric surgery to manage obesity - PubMed

Incretin polyagonists as an alternative to bariatric surgery to manage obesity - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/41884205/

Incretins are gut hormones involved in maintaining metabolic homeostasis in the human body, and disorders of the incretin system are recognized as contributing to the pathobiology of metabolic dysfunction and...

Review positions incretin polyagonists (e.g., tirzepatide) as potent non-surgical obesity alternatives to bariatric surgery, achieving comparable weight loss, glycemic control, and cardiometabolic benefits via multi-receptor gut hormone effects.

Profile Image
  • Saved
Falsely decreased triglyceride concentration in a patient with acute pancreatitis due to insufficient configuration of alarm rules - PubMed

Falsely decreased triglyceride concentration in a patient with acute pancreatitis due to insufficient configuration of alarm rules - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/41710254/

Acute pancreatitis is a potentially life-threatening complication of severe hypertriglyceridemia. The accurate measurement of triglyceride concentration is essential for diagnosis and therapeutic monitoring. This article presents a case of acute...

Case highlights falsely low triglyceride readings in hypertriglyceridemia-induced pancreatitis due to analyzer alarm failure; improved lab protocols, including lipemic index checks and enhanced alerts, are essential for accurate diagnosis.

Profile Image
  • Saved
The Lipoprotein(a) Implementation Gap: Bridging Evidence and Clinical Practice - PubMed

The Lipoprotein(a) Implementation Gap: Bridging Evidence and Clinical Practice - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/41789317/

Lipoprotein(a) [Lp(a)] represents one of cardiovascular medicine's most profound implementation gaps: a genetically determined risk factor affecting 1.5 billion people worldwide, yet historically underutilized in clinical practice despite overwhelming evidence...

Review highlights major implementation gap in lipoprotein(a) testing despite strong cardiovascular risk evidence. It discusses causal associations, evolving screening guidelines, and emerging RNA-targeted therapies achieving substantial Lp(a) reduction, advancing precision cardiovascular medicine.

Profile Image